Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
New role strengthens Quantori’s global leadership position in data science & digital IT
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Subscribe To Our Newsletter & Stay Updated